Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH4 | Q9H3N8 | 14/20 | 0.53 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.48 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.48 |
| ▸ | HTR3B | O95264 | 1/20 | 0.48 |
| ▸ | HTR3A | P46098 | 1/20 | 0.48 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.48 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.48 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.48 |
| ▸ | PAK4 | O96013 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4388702 | 0.87 | HRH4 (0.61) | HRH4HRH3 | |
| SCHEMBL4396416 | 0.87 | HRH4 (0.61) | HRH4HRH3 | |
| SCHEMBL4391967 | 0.87 | HRH4 (0.52) | HRH4HRH3 | |
| SCHEMBL4392752 | 0.87 | HRH4 (0.52) | HRH4HRH3 | |
| SCHEMBL4396473 | 0.85 | HRH4 (0.50) | HRH4HRH3 | |
| SCHEMBL4395534 | 0.84 | IDH2 (0.58) | HRH4HRH3LMNA | |
| SCHEMBL4388777 | 0.84 | HRH4 (0.49) | HRH4HRH3 | |
| SCHEMBL4398453 | 0.83 | HRH4 (0.53) | HRH4HRH3ROCK1 | |
| SCHEMBL27738440 | 0.81 | HRH4 (0.51) | HRH4HRH3HTR3EHTR3BHTR3A | |
| SCHEMBL27717385 | 0.81 | HRH4 (0.67) | HRH4HRH3HTR3EHTR3BHTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090306038-A1 | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity | PALAU PHARMA, S.A. (ES) | 2009-12-10 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090306038-A1 | 2-Aminopyrimidine derivatives as modulators of the histamine H4 receptor activity | HRH4, HRH2, HRH3 | HRH4 1/4885HRH3 3/4885HTR3E 68/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.